Neurocrine Bioscienc
(NQ:
NBIX
)
120.17
-1.04 (-0.86%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 6, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Neurocrine Bioscienc
< Previous
1
2
3
4
5
6
7
8
Next >
Neurocrine's Ingrezza Meets Primary Goal In Phase 3 Study In Patients With Involuntary Muscle Movement
December 08, 2021
Neurocrine Biosciences Inc (NASDAQ: NBIX) revealed topline data from its Phase 3 KINECT-HD study evaluating Ingrezza (valbenazine) for chorea associated with...
Via
Benzinga
Neurocrine Pens $2.6B Pact With Sosei Heptares For Neuro Targets
November 22, 2021
Neurocrine Biosciences Inc (NASDAQ: NBIX) has outlined a deal that provides Sosei Heptares Corporation $100 million upfront, R&D expenses, and a...
Via
Benzinga
Mobile Mental Health: Coming to a Home Near You?
November 18, 2021
Photo by Anna Shvets from Pexels The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial...
Via
Benzinga
Analyst Ratings For Neurocrine Biosciences
November 17, 2021
Neurocrine Biosciences (NASDAQ:NBIX) has observed the following analyst rat...
Via
Benzinga
Why Neurocrine Biosciences Shares Fell Nearly 10% Today
November 02, 2021
Investors have grown weary of unpredictable profitability and unexpected expenses.
Via
The Motley Fool
12 Health Care Stocks Moving In Tuesday's Intraday Session
November 02, 2021
Gainers Kiniksa Pharmaceuticals (NASDAQ:KNSA) stock increased by 16.73% to $14.86 during Tuesday's regular session. The current volume of 1.0 million shares is 269.7%...
Via
Benzinga
Week Ahead In Biotech (May 2-8): ChemoCentryx Adcom, Ophthalmology Conference Presentations, Earnings Deluge
May 01, 2021
Biopharma stocks experienced volatility in the week ended April 30, as stocks reacted to earnings, data readouts and a handful of FDA decisions. Earnings prints from big name...
Via
Benzinga
Exposures
Product Safety
Benzinga's Top Ratings Upgrades, Downgrades For November 19, 2021
November 19, 2021
Upgrades Morgan Stanley upgraded the previous rating for EQT Corp (NYSE:
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 17, 2021
November 17, 2021
Upgrades According to Williams Capital, the prior rating for On Holding AG (NYSE:
Via
Benzinga
What 5 Analyst Ratings Have To Say About Neurocrine Biosciences
November 02, 2021
Over the past 3 months, 5 analysts have published their opinion on Neurocrine Biosciences (NASDAQ:
Via
Benzinga
71 Biggest Movers From Yesterday
November 03, 2021
Gainers Avis Budget Group, Inc. (NASDAQ: CAR) shares climbed 108.3% to close at $357.17 on Tuesday after the company reported better-than-expected Q3 adjusted EPS and sales...
Via
Benzinga
The Daily Biotech Pulse: Pfizer Reports Solid Q3 Earnings, Regulatory Setback For Legend, Lilly to Supply Additional COVID-19 Antibody Cocktails To US
November 02, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus SAB Spikes On Analyst Action SAB Biotherapeutics, Inc. (NASDAQ: SABS) shares...
Via
Benzinga
Exposures
COVID-19
Neurocrine Biosciences, Inc (NBIX) Q3 2021 Earnings Call Transcript
November 01, 2021
NBIX earnings call for the period ending September 30, 2021.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
12 Health Care Stocks Moving In Monday's After-Market Session
November 01, 2021
Gainers Biophytis (NASDAQ:BPTS) shares mo...
Via
Benzinga
Neurocrine Biosciences: Q3 Earnings Insights
November 01, 2021
Neurocrine Biosciences (NASDAQ:NBIX) reported its Q3 earnings results on Monday, November 1, 2021 at 04:01 PM. Here's what investors need to know about the announcement....
Via
Benzinga
Neurocrine Biosciences's Return On Capital Employed Overview
November 01, 2021
According to Benzinga Pro, during Q2, Neurocrine Biosciences (NASDAQ:NBIX) earned $62.80 million, a 99.37% increase from the preceding quarter. Neurocrine Biosciences also posted...
Via
Benzinga
Looking into Neurocrine Biosciences's Return on Capital Employed
August 20, 2021
After pulling data from Benzinga Pro it seems like during Q2, Neurocrine Biosciences (NASDAQ:NBIX) earned $62.80 million, a 99.37% increase from the preceding quarter. Neurocrine...
Via
Benzinga
Earnings Scheduled For November 1, 2021
November 01, 2021
Companies Reporting Before The Bell • ANI Pharmaceuticals (NASDAQ:ANIP) is expected to report earnings for its third quarter. • Kiniksa Pharmaceuticals (NASDAQ:...
Via
Benzinga
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
October 31, 2021
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 14, 2021
October 14, 2021
Upgrades According to Roth Capital, the prior rating for Ring Energy Inc (AMEX:
Via
Benzinga
Stocks That Hit 52-Week Lows On Wednesday
August 11, 2021
On Wednesday morning, 67 companies achieved new lows for the year. Areas of Significance: Grifols (NASDAQ:GRFS) was the largest firm by market cap to set a new 52-...
Via
Benzinga
The Daily Biotech Pulse: Moderna's Vaccine Produces Durable Response Against Variants, FDA Approves Jazz's Sleep Disorder Drug, Dermata IPO
August 13, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 12) Adagio Therapeutics, Inc. (...
Via
Benzinga
Exposures
Product Safety
The Daily Biotech Pulse: Xeris Gets OK For Initiating Hyperthyroidism Study, Merck-Eisai Snag FDA Approval For Drug Combo, Decision Day For Jazz Pharma
August 12, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 11) Adagio Therapeutics, Inc. (...
Via
Benzinga
Exposures
Product Safety
The Daily Biotech Pulse: FDA Rejects FibroGen's Anemia Drug, Crinetics Gains On Positive Readout, BioCryst Withdraws Public Offering
August 11, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 10) Alnylam Pharmaceuticals,...
Via
Benzinga
Exposures
Product Safety
Benzinga's Top Ratings Upgrades, Downgrades For August 6, 2021
August 06, 2021
Upgrades According to Wolfe Research, the prior rating for The AES Corp (NYSE:
Via
Benzinga
Neurocrine Biosciences, inc (NBIX) Q2 2021 Earnings Call Transcript
August 03, 2021
NBIX earnings call for the period ending June 30, 2021.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Neurocrine Biosciences Inc (NBIX) Q1 2021 Earnings Call Transcript
May 06, 2021
NBIX earnings call for the period ending March 31, 2021.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Earnings Scheduled For August 3, 2021
August 03, 2021
Companies Reporting Before The Bell • Myriad Genetics (NASDAQ:MYGN) is likely to report earnings for its fourth quarter. • Stellantis (NYSE:STLA) is expected to...
Via
Benzinga
The Daily Biotech Pulse: Athenex, NeoGenomics And Amryt In M&A Mix, European Nod For Roche's Cancer Immunotherapy, Earnings Deluge Continues
May 05, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 4) AbbVie Inc. (NYSE: ABBV)...
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.